Kayhanian Hamzeh, Smyth Elizabeth C, Braconi Chiara
Hamzeh Kayhanian, Elizabeth C Smyth, Chiara Braconi, Department of Gastrointestinal Oncology, Royal Marsden Hospital, London and Surrey SM2 5PT, United Kingdom.
World J Gastrointest Oncol. 2017 Jul 15;9(7):268-280. doi: 10.4251/wjgo.v9.i7.268.
Cholangiocarcinoma (CCA) is a rare cancer arising from the biliary tree with a poor prognosis and limited therapeutic options. Recent large scale molecular characterisation studies have identified recurrent genetic alterations in CCA which may be amenable to therapeutic targeting. In this review we explore the genomic landscape of CCA and examine results from trials of molecularly targeted agents and immunotherapy in this disease. Challenges in CCA diagnosis, treatment and trial design are discussed and we reflect on future directions which may lead to improved outcomes for CCA patients.
胆管癌（CCA）是一种起源于胆管树的罕见癌症，预后较差且治疗选择有限。最近的大规模分子特征研究已经确定了CCA中反复出现的基因改变，这些改变可能适合进行靶向治疗。在这篇综述中，我们探讨了CCA的基因组格局，并研究了针对这种疾病的分子靶向药物和免疫疗法的试验结果。讨论了CCA诊断、治疗和试验设计中的挑战，并对可能改善CCA患者预后的未来方向进行了思考。
